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Background: Trichorhinophalangeal syndrome 1 (Trps1) gene is a member of GATA transcription factor family and has
an important function in tumorigenesis and progression. However, there are rare studies on its roles in carcinogenesis
and prognostic significance in human osteosarcoma.
Methods: The expression of Trps1 was detected by immunohistochemistry, and MVD was evaluated to determine the
amounts of microvessels by counting CD31-positive endothelial cells.
Results: Of the 74 cases that underwent study, Trps1-positive cases were 24. And it was associated with MVD significantly
(P = 0.008). The data also exhibited more cases of remote metastasis (P = 0.013) and higher Enneking stage (P = 0.017) in
Trps1-positive group compared to Trps1-negative group. Univariate analysis revealed that distant metastasis, MVD and
Trps1 expression were associated with a lower 3-year overall survival rate and disease-free survival rate (P = 0.003,
and P = 0.012 respectively). Furthermore, Trps1 and distant metastasis retained their significant prognostic effects
on patients survival rate by multivariate analysis (P < 0.05).
Conclusions: Trps1 plays a crucial role in osteosarcoma angiogenesis, metastasis and clinical surgical stage. Trps1 can be
a novel promising prognostic marker and therapeutic target, and antiangiogenic therapy which targets Trps1 molecule in
patients with osteosarcoma may lead to improved prognosis and longer-term survival.Background
Osteosarcoma is the most common primary malignant
bone tumors occurring in adolescents and young adults
[1–3]. Although various treatments such as wide excision
surgery of tumors, radiotherapy, chemotherapy as well as
neoadjuvant chemotherapy have made significant improve-
ments in the long-term outcome of these patients [4, 5], it
is still not satisfactory. There are still 30-40 % of children
dying of osteosarcoma, and 25 ~ 50 % of patients subse-
quently develop metastatic disease, which remains the
major cause of death [6]. Presence of primary metasta-
sis has been proved to be an independent prognostic
indicator in osteosarcoma [7].
The process of metastasis consists of a series of com-
plex procedures in which sustained angiogenesis plays a
crucial role [8–11]. Tumor angiogenesis depends on the* Correspondence: lilipathology@163.com
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thelial cells, and is regarded as a hallmark of cancer. It has
been clear that there is a significant correlation between
angiogenesis and prognosis in many cancers, including
gastric, colorectal, breast and prostatic cancers [12–15].
Several studies also have revealed high metastatic potential
and recurrence rate of osteosarcoma are associated with
high levels of angiogenesis [16, 17]. Anti-angiogenic ther-
apy which targets vascular growth within tumors with the
aim of suppressing tumor growth and metastasis is now
widely approved to treat different tumors. Anti-angiogenic
reagents theoretically have fewer side effects, because
neoangiogenesis rarely occurs in healthy adults.
Trps1 is a gene encoding a new member of GATA family
of transcriptional regulators and represses transcription of
genes containing -GATA- sequences. It consists of nine
zinc-finger domains, including a GATA-type zinc fin-
ger through which it binds DNA. Either mutation or
deletion of this gene causes a disease called Tricho-
rhino-phalangeal syndrome (TRPS) clinically which isstributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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Table 1 Correlation of clinicopathological variables with Trps1 in
human osteosarcoma
Variables Numbers Trps1 P
negative positive
Sex 0.434
male 51 33 18
female 23 17 6
Age 0.628
<20 34 22 12
≥20 40 28 12
Size 0.100
<8 cm 41 31 10
≥8 cm 33 19 14
Differentiation 0.091
well 11 10 1
poor 63 40 23
Position 0.329a
femur 37 22 15
tibia 16 12 4
others 21 16 5
Type 0.089a
common 62 39 23
special 12 11 1
Metastasis 0.013
yes 31 16 15
no 43 34 9
Enneking Stage 0.017b
I 11 10 1
II 58 39 19
III 5 1 4
aFisher’s exact test bLikelihood ratio
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Previous studies have proved that Trps1 is expressed in
several human malignant tumors and implied an import-
ant function in tumor growth, invasion, and metastasis
[18–20]. Furthermore, the abilities of chondrogenesis and
apoptosis in ATDC5 cells were enhanced by Trps1 [21].
And Trps1 has been shown to play pivotal roles in the de-
velopment of bone. Recently, it has been exhibited that
elevated Trps1 expression promoted angiogenesis by
affecting the expression of vascular endothelial growth
factor (VEGF) in breast cancer [22]. Hence, this current
study was designed to explore Trps1 expression and evalu-
ate its significance to intratumoural microvessels density
in osteosarcoma. Their associations between Trps1 and




A retrospective analysis showed that there were 157
patients who presented with osteosarcoma histopatho-
logically between March 2004 and August 2010 at the
Department of orthopedic surgery, Qilu Hospital of
Shandong University. Among them, in order to avoid
interfering, patients who did not receive neoadjuvant
treatment prior to diagnostic biopsy and whose paraffin-
embedded tissues are available for immunohistochemical
analysis were included. 74 eligible patients who underwent
tumor surgical resection and reconstruction or amputa-
tion were identified for this study. Clear margins were
achieved in all cases. These patients consisted of 51 males
and 23 females, and the age range was from 11 to 54 years
(median 25 years). Histologically, these osteosarcoma
samples included 62 cases of conventional type (42 os-
teoplastic, 13 chondroblastic and 7 fibroblastic type re-
spectively) and 12 cases of special type (5 parosteal, 1
periosteal, 5 low grade central and 1 telangiectatic type).
Tumor staging was evaluated based on the Enneking sur-
gical classification. 11 cases were at stageI, 58 at stage II, 5
at stage III. There were 7 cases of recurrence, and 31 cases
of distant metastasis comprising 5 of pre-surgical metasta-
sis and 26 of post-operative metastasis. In detail, the clini-
copathological parameters of these 74 cases were listed in
Table 1. This study was approved by the Ethics Committee
of Qilu Hospital and previous informed consent was ob-
tained from all patients.
Immunohistochemical Staining for Trps1 and CD31
Continuous sections in 4 μm thick were prepared from
each formalin-fixed, paraffin embedded tissue. Immuno-
histochemical staining was performed to evaluate the ex-
pression of Trps1 and CD31.
All sections on the slides were dewaxed, and rehy-
drated with xylene and graded alcohol, then dripped 3 %hydrogen peroxide on them to quench endogenous per-
oxidase. Afterwards, high-temperature antigen retrieval
was carried out in citrate buffer (pH 6.0) in a microwave
oven to enhance immunoreactivity, followed by 5 % nor-
mal horse serum to reduce the non-specific bindings.
Primary antibody against Trps1 (sc-26974, Santa Cruz
Biotechnology, Inc. USA, 1:200) and CD31 (Zhongshan
Biotechnology Company, Beijing, China) were applied to
the sections respectively and incubated overnight at 4 °C.
Subsequently, slides were incubated with the biotinylated
second antibodies and streptavidin–peroxidase conjugate,
and antibody-specific binding was visualized with 3, 3-
diaminobenzidine solution (DAB). Lastly, slides were
counterstained with hematoxylin and mounted. PBS
was used as a negative control by replacement of the
relevant primary antibody.
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Trps1 showed nuclear staining, and scoring was based
on a semi-quantitative scoring system according to both
the staining intensity (0, no staining; 1, weak; 2, moder-
ate and 3, intense staining) and percentage of positive
tumor cells on a 4-point scale as follows: 0, <5 % positive
cells; 1, 5 % ~ 25 % positive cells; 2, 26 % ~ 50 % positive
cells; 3, >50 % positive cells. The final staining score was
the multiplication of scores of staining intensity and per-
centage of positive cells. Cut-off levels were further ap-
plied as follows: 0 (−); 1–3 (+); 4–6 (++) and 7–9 (+++).
So the expression of Trps1 was divided into a non-
overexpression group (− or +) and an overexpression
group (++ or +++). Tumor microvessels were recorded
by counting the CD31-positive stained endothelial cells.
MVD was assessed according to a modified version of
the International Consensus Report [23]. Briefly, the im-
munostained sections were initially scanned at a low
power (100 × magnification) to identify “hot spots”,
which are the areas with the most intense vascularity.
Subsequently, counting of the stained microvessels was
performed on three consecutive high power (200 ×
magnification) fields within “hot spot”. Any yellow-
brown immunostained endothelial cells or endothelial
cell cluster that was clearly separate from adjacent
microvessels could be considered as a single countable
micovessel [13]. The average of three 200 × field micro-
vessel counts was captured as the value of MVD, and
the cut-off value for categorical evaluation of MVD
was predefined as the median microvessel count: Tumors
with microvessel numbers ≥median value were defined to
be high MVD group, while <median value were defined to
be low MVD group. Immunohistochemical analysis and
scoring were performed by two investigators (LL and
XJW) who were blinded to the diagnosis, clinical course
and outcome of patients independently.Follow-up
Follow-up period was defined from hospital discharge to
the date of patient’s death or the last follow-up, and data
were collected either on an outpatient basis or by tele-
phone interview. The living status was confirmed, and
the median period of follow-up was 40 months (range,
4–82 months). Overall survival (OS) was calculated from
the date of surgery to the date of death. Disease-free sur-
vival (DFS) time was defined as the interval between the
date of surgery and the date of recurrence. If recurrence
was not diagnosed, the survivors were censored on the
date of death or the last date of follow-up. Data involv-
ing the conventional clinicopathological parameters also
were collected for analysis, including gender, age, tumor
size, differentiation, position, metastasis and surgical
stage.Statistical Analysis
Statistical analyses were carried out by using the software
package SPSS 19.0 for Windows (SPSS Inc. Chicago,
USA). The Chi-square test was used for statistical analysis
between Trps1 and categorical data. Survival curves were
constructed through the Kaplan-Meier method and were
evaluated using the log-rank test. P values that less than
0.05 were considered to be statistically significant.
Results and Discussion
The expression of Trps1 and the correlation with MVD
The expression of Trps1 was detected in 24 of 74 (32.4 %)
cases, whereas 50 (67.6 %) cases showed negative staining
in tumor samples. Representative immunostaining with dif-
ferent intensities were shown in Fig. 1. In order to evaluate
the relationship between Trps1 and angiogenesis, microves-
sels were stained by CD31. Analysis of CD31 immuno-
stained sections demonstrated that the median MVD was
41 microvessels (range, 14 to 79). High MVD (≥41 micro-
vessels) was observed in 39 out of 74 cases (52.7 %). There
were 18 Trps1-positive (75 %) and 21 Trps1-negative
(42 %) samples respectively in high MVD group. There-
fore, it showed a significant correlation of Trps1 ex-
pression with MVD (P = 0.008). The Spearman correlation
analysis further proved these results (r = 0.355, P = 0.002,
Table 2).
Correlation of Trps1 expression with clinicopathological
variables in human osteosarcoma
We analyzed the effect of Trps1 expression on different
clinicopathological variables. As shown in Table 1, these
data exhibited the expression of Trps1 was not associated
with gender, age, tumor size, position, type and differenti-
ation (P > 0.05), but related with metastasis (P = 0.013)
and Enneking Stage (P = 0.017) significantly. Patients with
Trps1-positive expression had a higher tendency of both
distant metastasis and a further clinical stage.
The correlation of Trps1 expression with the prognosis in
patients with osteosarcoma
To provide a powerful explanation of the prognostic role
of Trps1, we assessed the effects of Trps1 expression on
the 3-year OS and DFS rates by Kaplan-Meier survival
analysis. In all 74 patients, tumor recurrence developed
in 31/74 (41.9 %), including distant metastasis in 24
cases, local recurrence in 5 cases and both in 2 cases.
Separately, tumor recurrence occurred in 14 out of 24
(58.3 %) cases with Trps1-positive while 17 out of 50
(34.0 %) cases with Trps1-negative. 49 patients died at
the end of follow-up period. Figure 2 showed the cumu-
lative OS and DFS curves of all 74 patients which were
stratified by Trps1 expression levels. 29 patients (39.2 %)
died within 3 years after operations, in which 14 cases
(58.3 %) showed Trps1-positive. Kaplan-Meier survival
Fig. 1 Trichorhinophalangeal syndrome type 1 (Trps1) and CD31 expression in osteosarcoma tissues by Immunohistochemical staining. CD31 indicates
intratumoural microvessels. Representative Fields showed the negative outcome of Trps1 and CD31 (upper row, ×200) and the positive outcome (lower
row, ×200). Trps1-positive staining was observed in nucleus. The cut-off value of microvessels was 41/×200 field
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Trps1-positive expression (P = 0.012, Fig. 2b). There was
a significant difference in 3-year OS rate between two
groups (P = 0.003, Fig. 2a).
Univariate and Multivariate Survival Analysis
Univariate and multivariate analysis were performed to in-
vestigate whether Trsp1 could be an independent factor to
predict prognosis among sorts of clinicopathological pa-
rameters (Table 3). Univariate analysis revealed that distant
metastasis, MVD and Trps1 expression were associated
with a poorer 3-year overall and disease-free survival rate
(P < 0.05) but were not associated with gender, age, tumor
position, size, histological type and differentiation (P > 0.05).
Further, with multivariate analysis, Trps1 and distant me-
tastasis retained their significant prognostic effects on
survival rate of patients (P < 0.05), however MVD didn’t
(P > 0.05),which indicated the possibility of cross-talk
between Trps1 expression and MVD. The influence of
MVD on prognosis in Univariate analysis could be
caused by Trps1 partly. These data demonstrated that
Trps1 affected tumor angiogenesis and could predictTable 2 The correlation of Trps1 protein with MVD
Trps1 Numbers MVD
High Low
Positive 24 18 6
Negative 50 21 29
aChi-square Test
bThe Spearman correlation was used to compare the degree of correlation. Positivesurvivals for patients with osteosarcoma as an independ-
ent prognostic factor.
Though known as the gene involved in TRPS, Trps1
has begun to attract wide attention on its roles in car-
cinogenesis. Trps1 was first discovered as one of the dif-
ferentially expressed genes between androgen-dependent
and androgen-independent prostate cancer cell lines.
Then Trps1 has been implicated in several human can-
cers, including breast cancer, leukemia, endometrial can-
cer and colon cancer. However, the roles of Trps1 in
tumorigenesis of osteosarcoma are still largely unclear
up to now. We investigated the expression of Trps1 in pri-
mary human osteosarcoma samples, and observed nuclear
stainings of Trps1 in 24 out of 74 cases with heteroge-
neous express pattern ranging from low to highly intense
staining. The expression of Trps1 was associated with dis-
tant metastasis and Enneking stage, but not associated
with patient age, tumor size, position, histological type,
differentiation. It indicated that Trps1 may be involved in
tumor genesis and progression of osteosarcoma, although
there are contradictory results about the role of Trps1 in
predicting tumor metastasis. It was reported that Trps1P valuea Spearman Value (r) P valueb
correlation
0.008 0.355 0.002
numbers reflected directed correlation
Fig. 2 Different Kaplan-Meier curves of overall and disease-free survival curves stratified in terms of the differential expression of Trps1. Figure 2a
showed that there was a significant difference in 3-year DFS rate between Trps1-positive and Trps1-negative (41.7 % vs 66 %, P = 0.012). Figure
2b showed a worse 3-year OS rate in Trps1-positive group (41.7 % vs 70.0 %, P = 0.003)
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dence indicated the high-level expression of Trps1 was
significantly associated with higher pathological stage and
positive lymph node metastasis [25].
Many studies have directed at determining the role of
angiogenesis, one hallmark of tumorigenesis, as well as
characterizing the role of several factors in the regula-
tion of microvessels growth [26]. It has been proved that
the reason was the imbalance between pro-angiogenic
factors and anti-angiogenic factors. As a result of the in-
duction of “angiogenic switch” during tumor develop-
ment, there is a threshold change between stimulatory
and inhibitory influences, in the favor of angiogenesis [27].Table 3 Univariate and multivariate analysis of different prognostic
Univariate analysis Multi
P1 P2 95.0 %
gender 0.136 0.570 0.289
age 0.054 0.097 0.665
position 0.238 0.054 0.391
size 0.389 0.602 0.289
type 0.091 0.068 0.343
differentiation 0.106 0.094 0.398
metastasis 0.001 0.001 0.003
MVD 0.027 0.028 0.821
Trps1 0.003 0.012 0.115
P1Overall survival rate, P2Disease-free survival rate, CI Confidence intervalOsteosarcoma is one of the most hyper-vascular tumors
characterized by active tumor angiogenesis. Tumor angio-
genesis plays a pivotal role in osteosarcoma development
and progression. Our current study is the first clinical re-
port to assess Trps1 expression in surgically resected
osteosarcoma, and also the first study to investigate the
role of Trps1 in relation to angiogenesis and prognosis of
osteosarcoma. We detected MVD in order to discover
whether Trps1-positive expression affects tumor angio-
genesis in osteosarcoma. Our results showed that tumors
with an over-expression of Trps1 tended to have a higher
MVD, which suggests Trps1 may promote progression of
aggressive phenotypes by inducting tumor angiogenesis inparameters
variate analysis
CI P1 95.0 % CI P2
~ 2.623 0.806 0.220 ~ 1.994 0.463
~ 6.486 0.209 0.837 ~ 8.657 0.097
~ 4.007 0.704 0.579 ~ 7.060 0.503
~ 1.744 0.455 0.314 ~ 1.964 0.605
~ 5.942 0.974 0.514 ~ 10.785 0.964
~ 8.899 0.425 0.386 ~ 4.977 0.617
~ 0.082 0.001 0.002 ~ 0.042 0.001
~ 5.597 0.119 0.859 ~ 6.252 0.097
~ 0.791 0.015 0.170 ~ 1.108 0.041
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genesis involves in multiple factors and steps, so far the
specific molecular mechanism of Trps1 promoting angio-
genesis in osteosarcoma is still unclear. Therefore, in light
of the findings of this current study, further research with
large sample size and osteosarcoma cell lines are needed
to validate the precise function of Trps1 in the future.
We further analyzed the correlation of Trps1 expression
with the post-operation 3-year survival rate. Kaplan-Meier
analysis showed after operation Trps1-positive group had
a worse both 3-year OS and DFS when compared with
Trps1-negative group, suggesting the potential function of
Trps1 as a promising prognostic marker for osteosarcoma.
In addition, both univariate and multivariate analysis
showed Trps1-positive expression retained its prognostic
value as an independent prognostic factor for unfavorable
survival. Interestingly, the prognosis significance in MVD
group by univariate analysis statistically disappeared in
multivariate analysis, it told us that tumor angiogenesis is
probably not the only pathway to affect prognosis for
Trps1. Whereas, Trps1 showed a favorable clinical prog-
nosis in breast cancer through regulating apoptosis and
MET [28, 29]. It was not difficult to find that the majority
of data were from endocrine-related cancers. More studies
from various tumors are needed to elucidate the exact
roles of Trps1 in carcinogenesis and progression. On the
other hand, Trps1 might exert its two distinct functions at
different times during tumor progression by reducing me-
tastasis but at later stages, acting to promote proliferation
and thereby worsening prognosis, as demonstrated by Wu
et al. Hereby we have the point to add that Trps1 might
have distinct functions in individual tumors and depend
on the context.Conclusions
In summary, based on the above results, we conclude that
Trps1 is associated with tumorigenesis, metastasis, surgical
stage and tumor angiogenesis in osteosarcoma positively, as
well as prognosis and survival. These findings provided im-
portant and new information on the metastasis of osteosar-
coma. The study indicated that Trps1 may have a clinical
potential not only as a promising prognostic marker, but
also as a novel therapeutic target in anti-angiogenesis for
osteosarcoma. However, validated research with larger sam-
ple capability and osteosarcoma cell lines need to be done
before Trps1 can be used for clinical decision-making.
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